Market momentum Vanda’s recent launch of NEREUS (tradipitant) and its commercial availability across the United States positions it as a growing consumer of specialty distribution and payer engagement services. Focus on market access strategy, patient support programs, and physician education to accelerate adoption in motion sickness and related indications.

Innovation emphasis Active development of VCA-894A for Charcot-Marie-Tooth disease and progress toward regulatory milestones indicates ongoing need for CNS and rare-disease commercialization expertise, including clinical development partnerships, orphan disease advocacy, and specialty channel partnerships.

Strategic partnerships Participation in high-profile industry events and boards suggests an opportunity to position as a collaborative partner for research, patient advocacy, and rare-disease initiatives, offering co-development, funding, and research collaboration channels.

Financial health With mid-range revenue and recent funding activity, there is potential for value-added services around market access, reimbursement strategy, and health economics outcomes research to strengthen payer and provider uptake for NEREUS and future therapies.

Global reach As a leading global biopharma with a broad technology stack and enterprise tooling, there is potential for selling digital health, data analytics, and cloud-enabled compliance solutions that support R&D, manufacturing, and regulatory processes across international markets.